acute myeloid leukemia infocenter

Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Cancer MoonShot 2020 will arm oncologists with new tools
Cancer MoonShot 2020 will arm oncologists with new toolsThe Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.
Three ways to maximize value in cancer treatmentAdvancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here’s how. Advancements in treatment show cancer trending towards a chronic condition. Align your cancer chronic care management team now. Here's how.
New cancer care challenges emergeCaring for survivors and finding best practices for new treatments
Achieving balance: Providing high-value cancer care
Achieving balance: Providing high-value cancer careHow plans can achieve the right balance between cost and outcomes